Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 10 Prostatic Neoplasms 8 Colonic Neoplasms 7 Neoplasms 5 Colorectal Neoplasms 5 Multiple Myeloma 4 Smoldering Multiple Myeloma 3 Monoclonal Gammopathy of Undetermined Significance 3 Lung Neoplasms 3 Uterine Cervical Neoplasms 2 Uterine Cervical Dysplasia 2 Stomach Neoplasms 2 Rectal Neoplasms 2 Radiodermatitis 2 Pancreatic Neoplasms 2 Pain 2 Esophageal Neoplasms 2 Breast Carcinoma In Situ 2 Adenomatous Polyposis Coli 2 cyclopia sequence 1 Uterine Neoplasms 1 Tuberous Sclerosis 1 Thrombocythemia, Essential 1 Stomatitis 1 Sezary Syndrome 1 Seizures 1 Psychological Well-Being 1 Prostate Cancer Metastatic Castration Resistant 1 Primary Myelofibrosis 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1

Interventions

Surveys and Questionnaires 5 pazopanib 3 Erlotinib Hydrochloride 3 Cetuximab 3 Vorinostat 2 Oxaliplatin 2 Bevacizumab 2 Azacitidine 2 temsirolimus 1 satraplatin 1 ixazomib 1 X-Rays 1 Videotape Recording 1 Valproic Acid 1 Trastuzumab 1 Sugars 1 Sorafenib 1 Platinum 1 Pemetrexed 1 Magnetic Resonance Spectroscopy 1 Leucovorin 1 Lenalidomide 1 Lapatinib 1 LY 2275796 1 Fluorouracil 1 Everolimus 1 Curcumin 1 Crizotinib 1 Capecitabine 1 Asian ginseng 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Advanced Cancers × Curcumin × Clear all

NCT01608139 2012-10-19

Study of Curcumin, Vorinostat, and Sorafenib

M.D. Anderson Cancer Center

Phase 1 Withdrawn

Advanced Cancers

Data powered by HemOnc (CC BY 4.0) Colophon ⚡